To assess the accuracy of the FUMO score in predicting the onset of overt Graves' orbitopathy (GO) in patients with Graves' disease (GD), highlighting its potential clinical significance.
Key Findings:
Medium-high risk patients developed overt GO more frequently than low-risk patients, indicating the need for closer monitoring.
GO was more active and moderate-to-severe in medium-high risk patients.
TRAb levels and FUMO score were the strongest independent predictors of GO, suggesting their importance in clinical assessments.
The model demonstrated good calibration and discrimination (AUC = 0.84; P < .0001).
High positive (73%) and negative (72%) predictive values were observed.
Interpretation:
Subclinical ocular alterations can predict the progression of GO in patients with GD, and the FUMO score effectively identifies at-risk individuals, emphasizing its clinical relevance.
Limitations:
No formal sample size calculation was performed prior to the study, which may affect the robustness of the findings.
The study's observational nature may limit causal inferences, introducing potential biases.
Conclusion:
The FUMO score, especially when combined with TRAb and FT3 levels, is a reliable tool for early risk stratification of patients at risk of developing overt GO, underscoring its clinical importance.
by Giulia Lanzolla, Francesca Saba, Silvia Corrias, Filippo Lixi, Giulia Faa, Alessandro Colleo, Chiara Mura, Gian Luigi Canu, Federico Cappellacci, Alberto Cuccu, Giuseppe Giannaccare, Stefano Mariotti, Francesco Boi
